These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

385 related items for PubMed ID: 2229304

  • 1. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man.
    Ghigo E, Goffi S, Nicolosi M, Arvat E, Valente F, Mazza E, Ghigo MC, Camanni F.
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1481-5. PubMed ID: 2229304
    [Abstract] [Full Text] [Related]

  • 2. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects.
    Arvat E, Gianotti L, Grottoli S, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F, Ghigo E.
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1440-3. PubMed ID: 7962341
    [Abstract] [Full Text] [Related]

  • 3. In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose.
    Maccario M, Procopio M, Grottoli S, Oleandri SE, Razzore P, Camanni F, Ghigo E.
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3774-8. PubMed ID: 8530634
    [Abstract] [Full Text] [Related]

  • 4. The decrease in growth hormone (GH) response after repeated stimulation with GH-releasing hormone is partly caused by an elevation of somatostatin tonus.
    Reichardt B, Schrader M, Mojto J, Mehltretter G, Müller OA, Schopohl J.
    J Clin Endocrinol Metab; 1996 May; 81(5):1994-8. PubMed ID: 8626871
    [Abstract] [Full Text] [Related]

  • 5. Repetitive GHRH administration fails to increase the response to GHRH in obese subjects. Evidence for a somatotrope defect in obesity?
    Ghigo E, Procopio M, Maccario M, Bellone J, Arvat E, Campana S, Boghen MF, Camanni F.
    Horm Metab Res; 1993 Jun; 25(6):305-8. PubMed ID: 8344645
    [Abstract] [Full Text] [Related]

  • 6. Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans.
    Gianotti L, Maccario M, Lanfranco F, Ramunni J, Di Vito L, Grottoli S, Muller EE, Ghigo E, Arvat E.
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3604-8. PubMed ID: 11061509
    [Abstract] [Full Text] [Related]

  • 7. Low doses of either intravenously or orally administered arginine are able to enhance growth hormone response to growth hormone releasing hormone in elderly subjects.
    Ghigo E, Ceda GP, Valcavi R, Goffi S, Zini M, Mucci M, Valenti G, Cocchi D, Müller EE, Camanni F.
    J Endocrinol Invest; 1994 Feb; 17(2):113-7. PubMed ID: 8006330
    [Abstract] [Full Text] [Related]

  • 8. Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration.
    Ghigo E, Arvat E, Rizzi G, Bellone J, Nicolosi M, Boffano GM, Mucci M, Boghen MF, Camanni F.
    J Endocrinol Invest; 1994 Mar; 17(3):157-62. PubMed ID: 8051337
    [Abstract] [Full Text] [Related]

  • 9. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
    Procopio M, Invitti C, Maccario M, Grottoli S, Cavagnini F, Camanni F, Ghigo E.
    Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336
    [Abstract] [Full Text] [Related]

  • 10. Age-related variations in the neuroendocrine control, more than impaired receptor sensitivity, cause the reduction in the GH-releasing activity of GHRPs in human aging.
    Arvat E, Ceda GP, Di Vito L, Ramunni J, Gianotti L, Broglio F, Deghenghi R, Ghigo E.
    Pituitary; 1998 Apr; 1(1):51-8. PubMed ID: 11081183
    [Abstract] [Full Text] [Related]

  • 11. Short-term fasting in obesity fails to restore the blunted GH responsiveness to GH-releasing hormone alone or combined with arginine.
    Procopio M, Maccario M, Grottoli S, Oleandri SE, Boffano GM, Camanni F, Ghigo E.
    Clin Endocrinol (Oxf); 1995 Dec; 43(6):665-9. PubMed ID: 8736266
    [Abstract] [Full Text] [Related]

  • 12. Evidence against depletion of the growth hormone (GH)-releasable pool in human primary hypothyroidism: studies with GH-releasing hormone, pyridostigmine, and arginine.
    Valcavi R, Valente F, Dieguez C, Zini M, Procopio M, Portioli I, Ghigo E.
    J Clin Endocrinol Metab; 1993 Sep; 77(3):616-20. PubMed ID: 8103770
    [Abstract] [Full Text] [Related]

  • 13. Arginine abolishes the inhibitory effect of glucose on the growth hormone response to growth hormone-releasing hormone in man.
    Ghigo E, Miola C, Aimaretti G, Valente F, Procopio M, Arvat E, Yin-Zhang W, Camanni F.
    Metabolism; 1992 Sep; 41(9):1000-3. PubMed ID: 1355580
    [Abstract] [Full Text] [Related]

  • 14. Pyridostigmine partially restores the GH responsiveness to GHRH in normal aging.
    Ghigo E, Goffi S, Arvat E, Nicolosi M, Procopio M, Bellone J, Imperiale E, Mazza E, Baracchi G, Camanni F.
    Acta Endocrinol (Copenh); 1990 Aug; 123(2):169-73. PubMed ID: 2220258
    [Abstract] [Full Text] [Related]

  • 15. Further evidence of cholinergic impairment of the neuroendocrine control of the GH secretion in Down's syndrome.
    Beccaria L, Marziani E, Manzoni P, Arvat E, Valetto MR, Gianotti L, Ghigo E, Chiumello G.
    Dement Geriatr Cogn Disord; 1998 Aug; 9(2):78-81. PubMed ID: 9524798
    [Abstract] [Full Text] [Related]

  • 16. Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects.
    Bellone J, Bartolotta E, Sgattoni C, Aimaretti G, Arvat E, Bellone S, Deghenghi R, Ghigo E.
    J Endocrinol Invest; 1998 Sep; 21(8):494-500. PubMed ID: 9801989
    [Abstract] [Full Text] [Related]

  • 17. Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion.
    Alba-Roth J, Müller OA, Schopohl J, von Werder K.
    J Clin Endocrinol Metab; 1988 Dec; 67(6):1186-9. PubMed ID: 2903866
    [Abstract] [Full Text] [Related]

  • 18. A neuroendocrinological approach to evidence an impairment of central cholinergic function in aging.
    Ghigo E, Goffi S, Arvat E, Imperiale E, Boffano GM, Valetto MR, Mazza E, Santi I, Magliona A, Boghen MF.
    J Endocrinol Invest; 1992 Oct; 15(9):665-70. PubMed ID: 1479149
    [Abstract] [Full Text] [Related]

  • 19. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
    Cordido F, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
    [Abstract] [Full Text] [Related]

  • 20. Low dose orally administered arginine is able to enhance both basal and growth hormone-releasing hormone-induced growth hormone secretion in normal short children.
    Bellone J, Bartolotta E, Cardinale G, Arvat E, Cherubini V, Aimaretti G, Maccario M, Mucci M, Camanni F, Ghigo E.
    J Endocrinol Invest; 1993 Feb; 16(7):521-5. PubMed ID: 8227981
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.